DE3587956T2 - Ausrüstung für die Verwendung bei der Behandlung von Osteoporose. - Google Patents

Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.

Info

Publication number
DE3587956T2
DE3587956T2 DE3587956T DE3587956T DE3587956T2 DE 3587956 T2 DE3587956 T2 DE 3587956T2 DE 3587956 T DE3587956 T DE 3587956T DE 3587956 T DE3587956 T DE 3587956T DE 3587956 T2 DE3587956 T2 DE 3587956T2
Authority
DE
Germany
Prior art keywords
regimen
daily doses
osteoporosis
treatment
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3587956T
Other languages
English (en)
Other versions
DE3587956D1 (de
Inventor
Vernon Albert Uchtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE3587956D1 publication Critical patent/DE3587956D1/de
Application granted granted Critical
Publication of DE3587956T2 publication Critical patent/DE3587956T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE3587956T 1984-04-30 1985-04-25 Ausrüstung für die Verwendung bei der Behandlung von Osteoporose. Expired - Fee Related DE3587956T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60554084A 1984-04-30 1984-04-30
US68456084A 1984-12-21 1984-12-21

Publications (2)

Publication Number Publication Date
DE3587956D1 DE3587956D1 (de) 1995-01-12
DE3587956T2 true DE3587956T2 (de) 1995-05-24

Family

ID=27084976

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8585200650T Expired - Fee Related DE3583887D1 (de) 1984-04-30 1985-04-25 Ausruestung fuer die behandlung der osteoporose.
DE3587956T Expired - Fee Related DE3587956T2 (de) 1984-04-30 1985-04-25 Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8585200650T Expired - Fee Related DE3583887D1 (de) 1984-04-30 1985-04-25 Ausruestung fuer die behandlung der osteoporose.

Country Status (12)

Country Link
EP (2) EP0162510B1 (de)
JP (1) JPH0655675B2 (de)
AT (2) ATE114473T1 (de)
AU (1) AU584611B2 (de)
CA (1) CA1277233C (de)
DE (2) DE3583887D1 (de)
DK (1) DK173735B1 (de)
FI (1) FI851686L (de)
HK (1) HK46694A (de)
IE (1) IE66497B1 (de)
NZ (1) NZ211925A (de)
PH (1) PH22622A (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
GR861167B (en) * 1985-05-02 1986-09-30 Research Corp Bone targeted inhibitors of carbonic anhydrase
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
HU215124B (hu) * 1991-02-26 1998-09-28 Norwich Eaton Pharmaceuticals, Inc. Eljárás csontritkulás (osteoporosis) kezelésére szolgáló ösztrogént és difoszfonátot tartalmazó, szinergetikus hatású gyógyszerkészítmények előállítására
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
CN1157565A (zh) * 1994-09-09 1997-08-20 普罗克特和甘保尔公司 用骨活性膦酸盐和甲状旁腺激素治疗骨质疏松症的方法
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
CA2208714C (en) * 1994-12-28 2003-10-21 Gador S.A. Bone mass anabolic composition comprising olpadronate
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
IL145124A0 (en) * 1999-03-05 2002-06-30 Procter & Gamble Methods of increasing bone volume using non-naturally-occuring fp selective agonists and antiresorptive compounds
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1317247A1 (de) * 2000-09-13 2003-06-11 The Procter & Gamble Company Kosmetisches verfahren zur behandlung der haut und/oder haare
LT3345607T (lt) * 2006-12-29 2023-01-10 Ossifi-Mab Llc Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis

Also Published As

Publication number Publication date
JPH0655675B2 (ja) 1994-07-27
EP0162510A1 (de) 1985-11-27
FI851686L (fi) 1985-10-31
DK173735B1 (da) 2001-08-20
ATE66608T1 (de) 1991-09-15
DE3587956D1 (de) 1995-01-12
IE851084L (en) 1985-10-30
AU584611B2 (en) 1989-06-01
AU4176985A (en) 1985-11-07
EP0162510B1 (de) 1991-08-28
FI851686A0 (fi) 1985-04-29
DK193585D0 (da) 1985-04-30
NZ211925A (en) 1989-01-06
HK46694A (en) 1994-05-20
EP0381296A1 (de) 1990-08-08
EP0381296B1 (de) 1994-11-30
CA1277233C (en) 1990-12-04
ATE114473T1 (de) 1994-12-15
DE3583887D1 (de) 1991-10-02
PH22622A (en) 1988-10-28
JPS6133117A (ja) 1986-02-17
DK193585A (da) 1985-10-31
IE66497B1 (en) 1996-01-10

Similar Documents

Publication Publication Date Title
ATE114473T1 (de) Ausrüstung für die verwendung bei der behandlung von osteoporose.
DE3579126D1 (de) Minocylin in stabiler form enthaltendes mittel zur behandlung periodontaler erkrankungen.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
EP0259440A4 (de) Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
FI873363A (fi) Foerfarande foer framstaellning av laekemedel med antitumoeraktivitet.
ES522918A0 (es) Procedimiento y aparato para el analisis de compuestos terapeuticos. otrosi.- se hace constar que el procedimiento y aparato que se reivindican en esta patente son inseparables y constituyen un solo objeto.
ES270679U (es) Transmision de correa dentada y poleas dentadas.
ES8801243A1 (es) Procedimiento para la obtencion de medicamentos que contienen 1-heteroaril-4--aril-pirazolin-5-onas.
GR3004103T3 (de)
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
ATE64300T1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
JO1521B1 (en) Amino Propene compounds are substituted amides, practical for their preparation, the agents they contain, their use, and new intermediate compounds produced in the preparation process.
DE3787386T2 (de) In der Behandlung von Östrogeninsuffizienz zu verwendende Zusammensetzung.
ES8404693A1 (es) Procedimiento de preparacion de nuevos amino-14 esteroides.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3685177D1 (de) Pharmazeutische zubereitung zur behandlung des bluthochdrucks.
GR3006434T3 (de)
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ZA815094B (en) Novel peptide
DE3686793D1 (de) Behandlung der reaktionsmischung bei der herstellung von natriumdithionit.
ATE34079T1 (de) Verwendung von carbamidperoxid zur herstellung eines arzneimittels zur behandlung von akne vulgaris.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee